CONCLUSIONS: Our results suggest that targeted therapies are safe in patients with SAPH. Controlled trials are warranted before therapeutic recommendations can be made.
PMID: 25078636 [PubMed - in process] (Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases)
Author:
